Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL